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Tumor cells that are nonsensitive to anticancer drugs frequently have a multidrug resistant (MDR) phenotype. Many studies with
cell lines and patient material have been done to investigate the impact of diﬀerent resistance markers at protein and mRNA level
in drug resistance but with contradictory outcome. In the present study, 26 well-characterised patient-derived non-small cell lung
cancer xenografts were used. The known chemosensitivity to etoposide, carboplatin, gemcitabine, paclitaxel and erlotinib was
compared to the protein and mRNA expression of BCRP, LRP, MDR1, and MRP1. Further, four of these xenografts were short-
termtreatedtoanalysepossibleregulationmechanisms aftertherapeuticinterventions.Wefoundaborderlinecorrelation between
the bcrp mRNA expression and the response of xenografts to etoposide. All other constitutive mRNA and protein expression levels
were not correlated to any drug response and were not signiﬁcantly inﬂuenced by a short term treatment. The present results
indicate that the expression levels of MDR proteins and mRNA investigated do not play an important role in the chemoresistance
of NSCLC in the in vivo situation.
Copyright © 2009 Jana Rolﬀ et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Lung cancer is still one of the most frequent cancers with
about 1 million incidences worldwide each year. The 5-year
survival rate is low with 10–15% compared to other cancers.
For chemotherapeutic treatment the classical drugs like
etoposide,gemcitabine,carbo-orcisplatin,vinorelbine,doc-
etaxel, and paclitaxel are used. For some years also targeted
therapies like tyrosine kinase inhibitors, like geﬁtinib, and
erlotinib have been introduced into clinical trials. However,
some patients seem to exhibit an intrinsic resistance or
develop an acquired resistance under treatment. It was
shownthatactivedrugeﬄuxtransportersoftheATPbinding
cassette (ABC) were involved that actively extrudes a range
of structurally and functionally diverse drugs [1, 2]. Three
human ABC transporters are primarily associated with the
multidrug resistance, namely, P-glycoprotein (P-gp, MDR1,
ABCB1), multidrug resistance protein 1 (MRP1, ABCC1),
and breast cancer resistance protein (BCRP, ABCG2). They
have broad and, to a certain extent, overlapping substrate
speciﬁcities and are involved in transport processes for a
variety of drugs used in chemotherapy. So it was shown
that etoposide can be transported by MRP1 [3] and MDR1
that is also able to cause resistance to bulky amphipathic
drugs, such as paclitaxel [1]. The lung cancer related protein
(LRP) is associated with multidrug resistance because it was
found to be overexpressed in an NSCLC cell line selected
for doxorubicin resistance that did not express MDR1 [4].
Moreover, it was reported that erlotinib was a substrate for
BCRP [5–7].
Most studies used only small numbers of lung cancer
cell lines selected for resistance or patient material that was
correlated with clinical features [8, 9]. It was turned out that
MRP1 played a major role in the intrinsic resistance. Further
on, an activation of MDR1 expression during chemotherapy
was suggested [10]. Additionally, it was shown that the2 Journal of Oncology
response to Taxol-based chemotherapy was related to MDR1
but not LRP expression [11]. These partially conﬂicting data
require further research.
Therefore we initiated a study in patient-derived NSCLC
xenografts that were not selected for resistance and revealed
a high coincidence with the original tumor [12]. We
wanted to address the question if the level of resistance
markers on mRNA or protein level is correlated with the
responseofxenograftstoclassicalcytotoxicdrugs(etoposide,
carboplatin, gemcitabine, and paclitaxel) or targeted therapy
(erlotinib).
2. Methods
2.1. Animal Experiments. 26 recently established NSCLC
xenografts were used for this study (Table 1). The chemosen-
sitivitywastestedrecently[12]soheredescribedonlyshortly.
All animal experiments were done in accordance with
the United Kingdom Co-ordinating Committee on Cancer
Research regulations for the Welfare of Animals and of
the German Animal Protection Law and approved by
the local responsible authorities. The chemotherapeutic
responsiveness of the passagable tumors was determined
in male NMRI:nu/nu mice. One tumor fragment each
was transplanted subcutaneously to the mice. At palpable
tumor size (50–100mm3) mice each was randomised to
treatment and control groups The following drugs and
treatment modalities were used: etoposide (Vepesid, Bristol-
MeyersSquibb)10mg/kg/d,qd1–5,i.p.;carboplatin(Mayne
Pharma Deutschland GmbH) 75mg/kg/d, qd 1 and 8, i.p.;
gemcitabine (Gemzar, Lilly Deutschland) 60–80mg/kg/d, qd
1, 4, 7, 10, i.p.; paclitaxel (Taxol, Sigma) 12.5mg/kg/d, qd 1–
5, i.v.; erlotinib (Tarceva, Hoﬀmann-LaRoche) 50mg/kg/d,
qd 1–5, 8–12, orally. Doses and schedules were chosen
according to previous experience in animal experiments and
represent the maximum tolerated or eﬃcient doses. The
injection volume was 0.2mL/20g body weight.
In this study, the four models 7406, 7433, 7700, and 7747
were selected because of their diﬀerential chemosensitivity
(Table 1). 7406 was choosen because it was the only model
that not responded to carboplatin and gemcitabine at once
but responded to erlotinib. The other models were randomly
selected but should represent the high response rates of all
tumors to carboplatin and paclitaxel (models 7433, 7747)
and gemcitabine and paclitaxel (7700). At the same time
they should not respond to more than two drugs to keep
the factors of inﬂuence low. For the short-term treated
xenografts three mice each were randomised to treatment
and control groups. The drug doses and application mode
were the same as described above except that the treatment
was carried out for three days. 24 hours after the last
treatment the mice were sacriﬁced, tumors were snap frozen
andstoredat−80◦C.TotalRNAandproteinwereisolatedfor
the analysis.
2.2. Real-Time PCR. RNA was isolated with RNA Isolation
Kit (Qiagen) according to the manufacturers instructions.
Total RNA was reversely transcribed using TaqMan Reverse
Transcription Reagents (Applied Biosystems (AB)) and Taq-
Man quantitative real-time PCR performed using cDNA
corresponding to 40ng RNA per reaction. Gene and species
speciﬁc primers for bcrp, lrp, mdr1, mrp1, and β-actin and
TaqMan Fast Mastermix (AB) were used according to the
manufacturers instructions and ampliﬁcations carried out
on the StepOne Plus Real-Time PCR system (AB) with 45
cycles. Each sample was done in two replicates. Normalised
ΔCT valueswereobtainedbysubtractingtheβ-actinCT from
the gene of interest CT. Tumor samples have been done 2-
fold and as positive controls MDA-MB-231/BCRP, A549 and
MT3/ADR were used.
2.3. Immunoblotting. Lysates for immunoblotting were pre-
pared by adding lysis buﬀer (150mM NaCl, 20mM Tris,
1% Triton X-100, 0,5% sodiumdesoxycholate, 0.5% SDS,
2mM EDTA, 2.5mM sodium pyrophosphate, 1mM β-
glycerophosphat; pH 7.7) containing protease and phos-
phatase inhibitors (Sigma-Aldrich) to the tumor tissue.
The protein concentration was determined using BioRad
Protein Assay (BioRad Laboratories GmbH). Tumor lysates
(20μg) were separated on 8% SDS-page polyacrylamide gels
and transferred to nitrocellulose membranes. Membranes
were blocked and incubated with the primary antibodies
(BCRP, 801-029-C125, Alexis; LRP, 610512, BD) overnight
at 4◦C. The secondary antibody (115-035-003, Jackson
Immuno Research) was conjugated with horseradish per-
oxidase. Protein bands were visualized using the enhanced
chemiluminescence detection system (GE Health Amersham
Life Science Inc). To verify equal protein loading, the blots
were stripped and reprobed for β-actin (Sigma). MDA-MB-
231/BCRP and A549 were used as positive controls.
2.4. FACS Analyses. One piece of each tumour was crudely
cut into smaller pieces and further separated with a cell
strainer till a cell suspension was obtained. Approximately
1 × 106 cells were used for analyses. After blocking with
goat serum, cells were incubated with the primary antibody
(MDR1 557001, BD; MRP1, 557594, BD) and secondary
Cy3-conjugated goat anti mouse antibody (115-165-146,
Jackson Immuno Research). As positive control MT3/ADR
breast cancer cells were used.
2.5. Statistical Analyses. Analyses of the mRNA or pro-
tein expression levels in comparison with the response to
treatment have been done. The correlation according to
Spearman and the P-values was calculated with the SPSS
software. The correlation coeﬃcient (r)c o u l dr a n g eb e t w e e n
0 (no correlation) and 1 (strong correlation).
3. Results
3.1. Constitutive Protein Expression in the 26 NSCLC Models.
BCRP protein was detected in 18/26 xenografts with a weak
to strong intensity. LRP could be found in 24 xenografts withJournal of Oncology 3
Table 1: Chemosensitivity testing, constitutive protein, and mRNA expression of BCRP, LRP, MDR1, and MRP1 in 26 xenografts and
the positive controls. Response: − negativ: 100–50% T/C, + 35–50% T/C, ++ 21–35% T/C, +++ 6–20%T/C, ++++ 0–5% T/C, tox-toxic,
n.t.—not tested; protein expression: − not detected, + weak, ++ medium, +++ strong expression; % of positive cells; mRNA expression:
normalised ΔCT values; etp—etoposide, carpl—carboplatin, gem—gemcitabine, paltx—paclitaxel, erlo—erlotinib.
Before treatment
Chemosensitivity Protein expression mRNA expression
LuCa etp Carpl gem paltx erlo BCRP LRP MDR1 [%] MRP1 [%] bcrp lrp mdr1 mrp1
7064 ++ −− ++ ++ − + 15.4 13.8 12.19 8.01 17.54 7.10
7126 −− +++ − ++ +++ + 15.3 18.2 4.17 5.04 18.18 3.45
7166 ++ ++ + −−− +++ 13.7 13.8 15.46 6.45 0 7.16
7177 − ++ +++ − ++ − ++ 14.5 29.5 10.42 5.33 16.97 2.02
7187 − ++ +++ −−−++ 15.4 18.3 8.13 6.90 0 7.55
7198 − +++ − +++ ++ 27.2 20.9 10.13 6.18 21.24 6.25
7298 + + ++ ++ −−++ 14.4 13.1 15.03 5.79 17.19 6.33
7336 − (+) ++ +++ − +++ + 13.3 13.6 8.08 6.68 0 7.02
7343 − +++ +++ ++ − + + 20.8 24.1 8.34 5.85 0 5.23
7387 −− +++ ++++ − ++ ++ 15.4 29.9 6.15 7.64 10.90 7.57
7406 + + +++ +++ − +++ + 29.4 22.4 14.87 7.61 14.97 8.10
7414 − ++ +++ +++ + − ++ 17.9 15.6 7.13 5.69 0 6.21
7433 − +++ − ++++ −− +++ 18.8 22.1 6.99 5.68 17.20 3.73
7462 − + ++++ +++ ++ + − 39.8 31.3 7.65 5.24 9.36 7.78
7466 −− ++++ ++++ ++ + ++ 15.5 18.6 8.62 7.56 22.43 8.65
7506 − ++++ (+) +++ − + + 65.8 19.0 10.96 7.07 15.94 6.98
7530 ++++ − tox +++ − +++ + 20.1 16.1 14.27 8.24 14.35 8.01
7558 − ++++ +++ −− +++ ++ 24.0 25.3 15.90 6.26 18.64 6.38
7612 − ++++ − +++ −−+ 17.7 15.5 11.09 5.89 16.98 6.04
7668 − +++ tox ++++ − +++ − 17.2 24.8 7.55 6.12 13.42 6.17
7700 −− ++++ ++ − ++ +++ 18.1 13.9 15.81 6.01 17.32 7.96
7747 − ++ − ++ − + ++ 62.0 15.0 15.19 4.82 18.29 6.26
7766 − +++ + ++ − + + 33.1 18.0 6.72 5.18 17.88 4.14
7860 + − ++ +++ − + ++ 20.6 22.4 11.16 4.96 16.41 5.47
7913 − + (+) +++ − + ++ 14.0 n.t. 13.50 5.64 18.47 6.17
7915 n.t n.t n.t n.t − + ++ 16.0 13.8 14.27 8.49 16.21 6.87
MDA-MB-231/BCRP 2.51
A549 9.97 5.54
MT3/ADR 3.49
diﬀerentexpressionlevels.TwoNSCLC7462and7668lacked
expression of LRP. MDR1 and MRP1 proteins were detected
in all xenografts with an almost equal expression level (see
Table 1).
3.2. Constitutive mRNA Expression in the 26 NSCLC Models.
Bcrp was expressed in the xenografts in a ΔCT range between
4 (7126) and 16 (7558). Mdr1 was detected in all xenografts
exceptinﬁve(7166,7187,7336,7343,and7414).Thehighest
expression with a ΔCT value of 9 was found in xenograft
7462, the lowest level with a ΔCT 22 in 7466. Nearly half
of the other xenografts (13) had ΔCT value in a dose range
between 15 and 19. The expression of mrp1 varied from ΔCT
v a l u e so f2t o8 .I n1 3x e n o g r a f t saΔCT value between 6 and
7 was found. The lrp levels ranged in all xenografts between
ΔCT 5 and 8, hence presenting a relatively homogeneous
expression. Bcrp and mdr1 had the most heterogeneous
mRNA expression pattern, and the overall expression level
oflrp and mrp1 was higher than that of bcrp and mdr1 in the
26 xenografts.
A borderline correlation between chemosensitivity and
mRNA expression was found in the comparison of etoposide
and bcrp (r = 0.490). All 6 xenografts sensitive to etoposide
showed a lower bcrp expression ΔCT 13,8 (±1.6) whereas
the resistant tumors had a mean ΔCT of 9,6 (±3.3). The
comparison of the lrp, mdr1, and mrp1 expression with the
chemosensitivity towards the diﬀerent drugs revealed no
further correlations.
3.3. mRNA Expression in the Xenografts after Short-Term
Treatment. RNA was isolated after short-term treatment of
the xenografts 7406, 7433, 7700, and 7747.
In all four xenografts the mRNA of bcrp, lrp, mdr1, and
mrp1 could be detected. For one and the same xenograft4 Journal of Oncology
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Figure 1: mRNA expression of bcrp, lrp, mdr1, and mrp1 after short-term treatment in xenografts 7406, 7433, 7700, and 7747. Treatment
was performed for three consecutive days. Three tumor samples per group were taken 24 hours after last treatment.
the mRNA expression was independent of the treatment
(Figure 1). The ΔCT values diﬀered in a range of two.
No signiﬁcant up- or down-regulations of the mRNA
after treatment with etoposide, carboplatin, gemcitabine,
paclitaxel, and erlotinib could be observed.
3.4. Protein Expression in the Xenografts after Short-Term
Treatment. The BCRP and MRP1 proteins were detected at a
medium or weak expression level, whereas LRP had a strong
expression in the all xenografts. MDR1 protein could be
found in all xenografts. All groups of one model showed
an equal expression level of BCRP, LRP, and MDR. There
w a sn or e g u l a t i o nd e t e c t a b l ea f t e rt r e a t m e n ti ne a c hN S C L C
xenograft (data not shown).
4. Discussion
A large number of studies dealing with questions of intrinsic
or acquired drug resistance used cell line-based approaches.
Hence, it was shown that ampliﬁcation and overexpression
of BCRP emerged as the dominant resistance mechanism
in MDR1 and MRP1-deﬁcient mouse ﬁbroblast and kidney
cell lines that were selected for resistance to etoposide [13].
In the present study, comparing etoposide response to bcrp
mRNA expression the tendency was shown that all sensitiveJournal of Oncology 5
xenografts had a lower expression level than the nonsensitive
tumors. Similar correlations could not be found at the
protein level. Recently, it was demonstrated that erlotinib
was a substrate for BCRP and MDR1 which may explain
the resistance seen in the clinics [6]. In our study, we did
not observe any correlation between response and BCRP or
MDR1 expression neither at protein nor at mRNA level.
Various studies showed that the expression of LRP
closely reﬂected the chemoresistance proﬁle of many tumor
cell lines and clinical cancer [4, 14–17]. Elevated LRP
levels were observed in cell lines resistant to cytotoxic
agents like doxorubicin, etoposide, vincristine, and cisplatin
[4, 18, 19]. In nonselected NSCLC cells LRP protein
and mRNA expression levels correlated with resistance to
cisplatin [20]. However, in the present study, no cor-
relation was observed regarding resistance to etoposide,
carboplatin or other drugs and the expression of LRP.
In other studies, likewise, no correlation with relevant
clinical or clinicopathological parameters could be demon-
strated [21, 22]. Anyway, in non-small cell and small cell
lung cancer patients, the expression was diﬀerent with
the highest expression found in chemoresistant NSCLC
[21].
In the present study, a relation of MRP1 expression
neither to cisplatin nor to etoposide response was seen.
In contrast, other authors reported that MRP1 expression
was correlated with lower chemosensitivity to etoposide,
but not to cisplatin in lung cancer cell lines and patients
[8,23,24].NSCLCpatientswerefoundtoexhibitmostlylow,
but occasionally high MRP1 mRNA expression levels [25].
Another study indicated that either one, or both, MDR1 or
MRP1wasfrequentlyexpressedinNSCLC,andexpressionof
mrp1 was found to be predominant over mdr1 at the mRNA
level [26]. This could be conﬁrmed in the present study as
it detected almost equal mRNA expression levels among the
xenografts. In general, the mrp1 level was higher than that of
the mdr1.
For MDR1 expression also contradictory literature exists.
Some concluded that Taxol-based chemotherapy response
of NSCLC patients was related to MDR1 but not LRP
expression [11] while others suggested that MDR proteins
(LRP, MDR1, and MRP1) may not play an important role
in the chemoresistance and drug eﬄux of NSCLC cells [9].
We were not able to demonstrate any correlation between
the chemosensitivity and the expression of MDR. Even after
short-term treatment no remarkable changes of mRNA or
protein could be observed.
Onereasonforthediﬀerentresultsdescribedinliterature
and found by us could be the model system used. While we
used patient-derived xenografts that were not selected for
any drug resistance, many other studies included cell lines
passagedoveryearsorselectedforresistanceunderhighdrug
concentrations. The in vivo situation is diﬀerent because the
drug availability and exact “in-tumor” concentration are not
exactly known. However, the response rates of xenografts
were similar to those observed in human Phase II studies
with the same agents [12, 27]. Patient-derived xenografts
allow the detailed investigation of therapy related markers
and their dynamic regulation in a well-standardized and
clinically related way.
Moreover, the multidrug resistance is regarded to be a
multifactorial phenomenon in which more than the markers
studied in the present study could be involved.
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